PPARA and metabolic syndrome: Saroglitazar, a dual-PPARα/γ agonist, in a randomized, double-blind, placebo-controlled study (EVIDENCES IV, NCT03061721), significantly improved liver function, serum ALT, insulin resistance and atherogenic dyslipidemia [129].